Cipla Ltd. (CIPL)

889.25
-5.70(-0.64%)
  • Volume:
    2,470,405
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    884.00 - 898.30
  • Type:Equity
  • Market:India
  • ISIN:INE059A01026
  • S/N:CIPLA

CIPL Overview

Prev. Close
894.95
Day's Range
884-898.3
Revenue
207.99B
Open
898.3
52 wk Range
738.1-1,005
EPS
32.03
Volume
2,470,405
Market Cap
717.44B
Dividend (Yield)
5.00
(0.55%)
Average Vol. (3m)
2,437,485
P/E Ratio
27.94
Beta
0.34
1-Year Change
16.6%
Shares Outstanding
806,786,839
Next Earnings Date
Feb 09, 2022
What is your sentiment on Cipla Ltd.?
or
Market is currently closed. Voting is open during market hours.

Cipla Ltd. Company Profile

Employees
25672
Market
India

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other dosage forms consists of injectables and biosimilars. Cipla Limited has collaboration with CSIR-Indian Institute of Chemical Technology for the development of medication for the treatment of COVID-19; partnership with Karwa Ltd. for the commercialization of antibody detection kits for COVID-19; partnership with the Premier Medical Corporation Private Limited for the commercialization of the rapid antigen test kits for COVID-19; licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellSellStrong SellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy
  • Is it right time to buy?
    0
    • hi sry for the delay. sure buy 919 sell 940
      0
  • statup taking today tommrrow 915
    0
    • 910 support level .wait and buy. trend reversal will happen means we will buy
      0
      • Siripurapu Rambabu  no please wait. 894 support than trend reversal will happen.
        0
      • Siripurapu Rambabu  did you check any graph?
        0
      • wait it will reach again 1000 within a month
        0
    • hi, can someone giude what is cipla view for tommorow, will buy or sale
      0
      • sell only please wait
        0
    • ANY ONE PLEASE VIEW ON CIPLA
      0
      • still trend weak wait 904 after we see
        0
    • CIPLA VIEW FOR TOMORROW?
      0
      • I have 930 Ce@ 13 rs Should I hold or exit
        0
        • I hope u exited from your call if not first thing to be done on Monday morning to come out of this as in this series it's doubtful to go in profits.
          0
        • yes exited
          0
      • plz view on cipla I have 950 Ce @32 now 11 can I hold or exit
        0
        • do average with one more lot on Monday and wait for good return next week end
          0
      • Buy cipla 950 CA at cmp 9 sl 7 tgt 16 and 20
        1
        • Buy CONFIPET at 62 short term target 80++
          0
          • Buy HINDCOPPER at 145-147 Target 170 to 200++
            0
            • any news
              0
              • Buy bandhan bank at 340 shrot term target 400++
                0
                • cipla ka devident account me kb credit hoga
                  0
                  • strong BUY for cipla for tgt of 1005 still 28 June 2021
                    0
                    • any view for cipla on Monday I am holding 950 CE
                      0
                      • hold highest open interest at 950 ce
                        0
                    • what is may expiry target for cipla
                      0
                      • buy cipla 882 target 900 ..
                        0
                        • cipla has a strong support st 870 strong momentum buy as much as u can it will go till 1000 in two months
                          0
                          • cipla can reverse from here on results bashing is finished by end of the day
                            0
                            • no Results are not as per expectations but still results are good. company has decreased margin as well. TGT will be 1020-30. yes operator can push this down to 3 5 percent to punish the stock as it was not as per their expectations.
                              0
                              • monday open 960 then 1000
                                0
                                • keep short position now
                                  0
                                  • cipla to gayo not a good result
                                    0
                                    • Fantastic Result expected, CIPLA target 970- 1000++
                                      0
                                      • okay
                                        0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.